첫 페이지 News 본문

According to AI News, on December 20th, the pre-market decline of Novo Nordisk's US stock market narrowed to 20%, after a previous drop of nearly 30%, the largest single day decline on record, as the trial results of Novo Nordisk's weight loss drug CagriSema did not meet expectations.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

六月清晨搅 注册会员
  • Follow

    0

  • Following

    0

  • Articles

    30